Loading
A phase 3 trial of Durvalumab, Tremelimumab in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.
Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC is a phase 3 interventional study registered as NCT05557838 by AstraZeneca, with 214 participants enrolled, started 2023-02-15 and due to reach its primary completion in 2026-09-30. Interventions recorded: Durvalumab, Tremelimumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), Durvalumab, AstraZeneca.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), Durvalumab, AstraZeneca.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), Durvalumab, AstraZeneca.
Shares Tremelimumab, Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Tremelimumab, Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), AstraZeneca, Hepatocellular carcinoma.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), AstraZeneca, Hepatocellular carcinoma.
Shares Durvalumab, AstraZeneca, Hepatocellular carcinoma, Immune checkpoint inhibitors.